Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Advanced Prostate Adenocarcinoma Clinical Trial

Official title: Efficacy, Safety, and Pharmaco-kinetics of Leuprolide Acetate for Injection 3.75mg (Depot) (Leuprorelin) Administered in Subjects With Advanced Adenocarcinoma of Prostate: A Randomized, Active Controlled, Comparative, Open-Label, Multi-Center, Phase 3 Study

Status Completed

Clinical Trial Summary

This is a Randomized, Active Controlled, Comparative, Open-Label, Multi-Center, Phase 3 clinical study to compare the efficacy, safety, and pharmacokinetics of leuprolide acetate for injection 3.75mg (depot) of two brands (Luprodex and Lucrin) administered in subjects with advanced adenocarcinoma of the prostate. Approximately 168 subjects (males )of age above 18 years fulfilling the eligibility criteria will be enrolled. The IP will be given as a monthly dose for two cycles on day 0 and day 28. The pharmacokinetic analysis will be done for 12 patients receiving Luprodex. The primary and secondary outcomes will be captured on days as per protocol. Adverse events will be noted for safety evaluation.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Adenocarcinoma
• Advanced Prostate Adenocarcinoma

• NCT number: NCT04914195
• Study type: Interventional
• Source: Bharat Serums and Vaccines Limited
• Status: Completed
• Phase: Phase 3
• Start date: July 1, 2021
• Completion date: September 29, 2022